Bangkok Genomics Innovation Pcl
Bangkok Genomics Innovation Public Company Limited provides medical analysis services in Thailand. The company offers screening for fetal chromosomal abnormalities using non-invasive prenatal testing under the NIFTY brand; preimplantation chromosomal abnormality and thalassemia carrier gene screening; infectious disease group analysis; testing for human papilloma virus; and monkeypox virus, COVID… Read more
Bangkok Genomics Innovation Pcl (BKGI) - Total Assets
Latest total assets as of September 2024: ฿591.32 Million THB
Based on the latest financial reports, Bangkok Genomics Innovation Pcl (BKGI) holds total assets worth ฿591.32 Million THB as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bangkok Genomics Innovation Pcl - Total Assets Trend (2018–2023)
This chart illustrates how Bangkok Genomics Innovation Pcl’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Bangkok Genomics Innovation Pcl - Asset Composition Analysis
Current Asset Composition (December 2023)
Bangkok Genomics Innovation Pcl's total assets of ฿591.32 Million consist of 72.4% current assets and 27.6% non-current assets.
| Asset Category | Amount (THB) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ฿0.00 | 43.0% |
| Accounts Receivable | ฿29.36 Million | 10.0% |
| Inventory | ฿10.05 Million | 3.4% |
| Property, Plant & Equipment | ฿0.00 | 0.0% |
| Intangible Assets | ฿1.08 Million | 0.4% |
| Goodwill | ฿0.00 | 0.0% |
Asset Composition Trend (2018–2023)
This chart illustrates how Bangkok Genomics Innovation Pcl's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bangkok Genomics Innovation Pcl's current assets represent 72.4% of total assets in 2023, an increase from 53.3% in 2018.
- Cash Position: Cash and equivalents constituted 43.0% of total assets in 2023, up from 14.3% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 10.0% of total assets.
Bangkok Genomics Innovation Pcl Competitors by Total Assets
Key competitors of Bangkok Genomics Innovation Pcl based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
Bangkok Genomics Innovation Pcl - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Bangkok Genomics Innovation Pcl generates 0.84x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Bangkok Genomics Innovation Pcl generates $ 10.97 in net profit.
Bangkok Genomics Innovation Pcl - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.59 | 7.72 | 4.66 |
| Quick Ratio | 10.07 | 6.98 | 4.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ฿456.44 Million | ฿ 182.15 Million | ฿ 107.56 Million |
Bangkok Genomics Innovation Pcl - Advanced Valuation Insights
This section examines the relationship between Bangkok Genomics Innovation Pcl's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.47 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -2.5% |
| Total Assets | ฿293.02 Million |
| Market Capitalization | $8.21 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bangkok Genomics Innovation Pcl's assets below their book value (0.03 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Bangkok Genomics Innovation Pcl's assets decreased by 2.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Bangkok Genomics Innovation Pcl (2018–2023)
The table below shows the annual total assets of Bangkok Genomics Innovation Pcl from 2018 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | ฿293.02 Million | -2.51% |
| 2022-12-31 | ฿300.58 Million | +60.11% |
| 2021-12-31 | ฿187.74 Million | +91.78% |
| 2020-12-31 | ฿97.89 Million | +84.09% |
| 2019-12-31 | ฿53.18 Million | -9.61% |
| 2018-12-31 | ฿58.83 Million | -- |